FDA Approved: DOVATO — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

FDA approved a supplemental application for DOVATO, a fixed-dose combination of dolutegravir and lamivudine, developed by ViiV Healthcare.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dovato (dolutegravir/lamivudine)

Snippet

SUPPL AP for DOVATO (DOLUTEGRAVIR SODIUM AND LAMIVUDINE)